Latest news

• Sanofi trumpets new IGlarLixi data after regulatory delay

  Sanofi trumpets new IGlarLixi data after regulatory delay. Reports that the combination drug is more effective at controlling glucose than Lantus alone. ... Sanofi is highlighting new data for its IGlarLixi combination drug for diabetes showing it is

• Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

  Sanofi loses lead on diabetes combo IGlarLixi after FDA delay. FDA verdict on Novo Nordisk’ s rival combo Xultophy due next month . ... The FDA is due to deliver a verdict on Xultophy next month, with a decision on IGlarLixi now pushed out to the end

• Sanofi boosted by iGlarLixi trials at ADA

  Sanofi boosted by iGlarLixi trials at ADA. Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes. ... The positive data comes as iGlarLixi approaches an FDA decision on approval - due in August - after a positive

• FDA panel backs Sanofi's insulin/GLP-1 agonist combo

  FDA panel backs Sanofi's insulin/GLP-1 agonist combo. iGlarLixi secures endorsement despite concern over its dosing and delivery device. ... iGlarLixi and other new drugs such as longer-acting Lantus follow-up Toujeo are considered key to Sanofi's

• FDA advisors back Novo Nordisk's IDeglira combination

  The committee's decision could also give Novo a boost over its diabetes rival Sanofi, whose similar combination of iGlarLixi (which brings together Lantus and Lyxumia) is due to be reviewed